Testing CAR-T cell therapy for high-risk multiple myeloma or plasmacytoma
Tests CAR-T cells, made from a patient's own immune cells, in adults with high-risk myeloma.
Plain-language title generated from the registry record
Registry title: Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06429150, who can take part
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT06429150
- Record updated
- 2 November 2026
- Original description
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.Read full original descriptionShow less
Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Inclusion: Male and female subjects with multiple myeloma or plasmacytoma; Strictly complete remission (sCR) is a treatment goal; Expected survival > 12 weeks; After prior auto-SCT is eligible regardless of other prior therapies; Adequate venous access for apheresis, and no other contraindications for leukapheresis; Voluntary informed consent is given and commitment to continued follow-up.
Exclusion: Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary; Uncontrolled active infection; Active HIV, hepatitis B or hepatitis C infection; Any medical conditions that may preclude participation; Pregnant or lactating women.